- CA$19.91m
- CA$20.18m
- CA$16.48m
- 90
- 63
- 50
- 77
Annual balance sheet for NexgenRx, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.802 | 2.32 | 1.77 | 1.88 | 1.71 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.355 | 0.479 | 0.41 | 0.778 | 0.874 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 18.4 | 20.8 | 18 | 23.3 | 24.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.692 | 0.504 | 0.835 | 0.809 | 0.826 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 25.2 | 29.4 | 25.7 | 30.2 | 30.5 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 19 | 19.6 | 16.5 | 22.1 | 22.4 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Liabilities | 19.7 | 19.7 | 16.9 | 22.5 | 22.8 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 5.52 | 9.71 | 8.85 | 7.71 | 7.62 |
Total Liabilities & Shareholders' Equity | 25.2 | 29.4 | 25.7 | 30.2 | 30.5 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |